The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Eslami, G; Mousaviasl, S; Radmanesh, E; Jelvay, S; Bitaraf, S; Simmons, B; Wentzel, H; Hill, A; Sadeghi, A; Freeman, J; Salmanzadeh, S; Esmaeilian, H; Mobarak, M; Tabibi, R; Kashi, AHJ; Lotfi, Z; Talebzadeh, SM; Wickramatillake, A; Momtazan, M; Farsani, MH; Marjani, S; Mobarak, S

Mobarak, S (corresponding author), Abadan Fac Med Sci, Abadan, Iran.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020; 75 (11): 3366

Abstract

Objectives: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro e......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索